It was a pleasure to meet Dr Aus Alzaid at the European Society for the Study of Diabetes (EASD) Annual Meeting in Barcelona to discuss the latest knowledge and insights on the use of sulfonylureas in the treatment of type 2 diabetes.
Questions:
1. Following the emergence of new classes of glucose-lowering drugs, where do sulfonylureas (SUs) fit into the treatment paradigm for type 2 diabetes? (0:04)
2. What do the latest guidelines recommend for the use of SUs? (1:00)
3. Have the SUs been formally tested for cardiovascular safety in cardiovascular outcome trials (CVOTs)? (2:19)
4. What are the benefits and risks of using SUs as an add-on to metformin? (5:09)
5. How do you expect the role of SUs to evolve in the future? (6:28)
Aus Alzaid has no conflicts of interest to declare in relation to this video.
Filmed at the Annual Meeting of the European Association of the Study of Diabetes (EASD) Barcelona, Spain 2019.
